Compare Natera Inc. Common Stock (NTRA) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Oxford Lane Capital Corp — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Oxford Lane Capital Corp trades at $8.22 (market cap $806.30M). The key difference: Natera Inc. Common Stock is far larger — about 70.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 29.18% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Oxford Lane Capital Corp for 51 Days on average.
| NTRA | OXLC | |
|---|---|---|
Market Cap | $57.03B | $806.30M |
Volume | 1,131,157 | 1,199,574 |
Sector | Health | Financials |
52-Week High | $425.64 | $16.02 |
52-Week Low | $179.42 | $8.15 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $56.18B | $1.20B |
Dividend Yield | — | 29.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
OXLC trades at $8.34, down 3.02% over the past day, with a bearish technical outlook from moving averages and oscillators. The stock shows a low P/B of 0.78 but negative ROE and ROA, alongside recent earnings misses. Dividends of $0.20 per share are being paid regularly, but cash flow from operations is negative, and 2026 revenue and profit trends are sharply negative. Analyst sentiment is mixed with a 50% buy rating.
The outlook is cautious due to deteriorating fundamentals, including a projected $585M net loss for 2026 and unsustainable dividend payouts relative to earnings. Key risks include high leverage, volatile CLO investments, and potential NAV erosion. Upside may exist if CLO markets stabilize, but current data suggests significant headwinds for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
